QTREX Quantum Ltd. (QTEX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.22 (-7.58% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTEX ranks #816 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, LNSR (LENSAR Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue, -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0.2% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While QTEX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.09) and Max Pain ($1.28) forces dealer call-delta covering toward $4.04.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
QTREX Quantum Ltd. (QTEX) dropped -7.58% to $1.22, trading at 26% of its 52-week range ($0.28 – $3.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Ness Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrast
QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, announced today that
6,785,715 warrant shares registered in July 2026 exercised in full. QTREX currently has no investor warrants, ATM, and no convertible securities outstandingNess Ziona, Oct. 14, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd.
6,785,715 warrant shares registered in July 2026 exercised in full. Qtrex currently has no investor warrants at the market programs, and no convertible securities outstandingNess Ziona, Oct. 14, 2026 (GLOBE NEWSWIRE) --
Shares back above $1.00 for 6 consecutive trading days Ness Ziona, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”), a company focused on advancing Additively Manufac
On the strength of these results, definitive agreement with the testing company being finalized; its name, business and the full agreement to be disclosed within weeks.Ness Ziona, Oct. 01, 2026 (GLOBE NEWSWIRE) -- QTREX
Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Record first half revenue of $1.55 million, up 438%, at a 61% gross margin, all generated by the AME and Quantum segment in its first 86 days after being acquired by
Ness Ziona, Sept. 02, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure
The Company will publicly unveil the architecture to the global quantum computing industry at IEEE Quantum Week 2026 in Toronto on September 13thNess Ziona, Aug. 31, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: Q
Following the debut, QTREX will launch structured configuration programs to translate customer requirements into engineering configurations and commercial proposals for customer-specific systemsNess Ziona, Aug. 31, 2026
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on QTEX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for QTEX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, QTREX Quantum Ltd. (QTEX) ranks #816 by composite RQD confidence (31/100, grade E) and #699 by equity capitalization ($73.9M). Within this direct 5-issuer industry benchmark cohort, QTEX leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QTEX at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QTEX
ACTIVE
QTREX Quantum Ltd. | E | 31/100 | — | 0.7% | -35.0% | -7.58% | $73.9M | Benchmark Subject |
| LNSR LENSAR Inc. | E | 24/100 | — | 39.4% | -35.0% | -2.18% | $73.3M | /lnsr-vs-qtex → |
| MBOT Microbot Medical Inc. | D- | 41/100 | — | — | -15.8% | -2.68% | $75.2M | /mbot-vs-qtex → |
| DAVI Davion Healthcare Plc | D | 47/100 | — | — | — | -37.55% | $67.3M | /davi-vs-qtex → |
| SKIN SkinHealth Systems Inc. (Class A) | D- | 36/100 | — | 65.3% | -26.9% | -2.07% | $66.0M | /skin-vs-qtex → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), QTREX Quantum Ltd. (QTEX) reported GAAP revenue of $289.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.2M, operating cash flow of -$9.9M, and free cash flow of -$10.0M (-4.5% YoY). On the balance sheet, QTEX closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $289.0K | -$13.2M | -$9.9M | -$10.0M | $5.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$11.1M | -$9.4M | -$9.5M | $8.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$11.3M | -$9.7M | -$9.7M | — | — |
As of 2026-11-02, QTREX Quantum Ltd. (NASDAQ: QTEX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.22 (-7.58% 1D, market cap $73.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QTEX ranks #816 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), QTEX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -35.0%. By comparison, LNSR (LENSAR Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $73.3M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, QTEX leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
Per QTEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837493), QTREX Quantum Ltd. generated $289.0K in revenue, -$13.2M in net income, and -$10.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
QTEX last traded at $1.22 (-7.58% on volume of 2,795,072 shares), positioning the stock +11.93% above its 50-day simple moving average ($1.09) and +25.77% above its 200-day simple moving average ($0.97). Across its 52-week range of $0.28 to $3.85, QTEX sits at the 26.3% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.07 to $1.37).
Why QTEX Stock dropped -7.58% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD 5-pillar rating engine, QTREX Quantum Ltd. (QTEX) carries a composite score of 31 / 100 (E — Roarable Strong Sell — Forensic Risk / Avoid).\n- Fundamental Cash Engine (7 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of -13.49% and gross margin of 0.7%.\n- Institutional 13F Whale Flow (7 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Medical/Dental Instruments cohort.\n- Insider & Congressional Conviction (3 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (6 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (8 / 20): Altman Z-Score of 2.50, Piotroski F-Score of 2/9, and Debt-to-Equity of 0.50.
QTREX Quantum Ltd. (QTEX) is a NASDAQ-listed Health Care issuer operating in Medical/Dental Instruments with a market capitalization of $0.1B.
Operating within Medical/Dental Instruments (Health Care), QTEX exhibits an operating margin of -60.0% and net margin of -60.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (0.7%), and valuation discipline (current multiple) relative to free cash flow conversion.
Real-time company headlines, analyst actions, and sector developments for QTREX Quantum Ltd. (QTEX) • Click "Debate This Headline" to argue it in the Roar Pit below
Ness Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrast
QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, announced today that
6,785,715 warrant shares registered in July 2026 exercised in full. QTREX currently has no investor warrants, ATM, and no convertible securities outstandingNess Ziona, Oct. 14, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd.
6,785,715 warrant shares registered in July 2026 exercised in full. Qtrex currently has no investor warrants at the market programs, and no convertible securities outstandingNess Ziona, Oct. 14, 2026 (GLOBE NEWSWIRE) --
Shares back above $1.00 for 6 consecutive trading days Ness Ziona, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”), a company focused on advancing Additively Manufac
On the strength of these results, definitive agreement with the testing company being finalized; its name, business and the full agreement to be disclosed within weeks.Ness Ziona, Oct. 01, 2026 (GLOBE NEWSWIRE) -- QTREX
Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Record first half revenue of $1.55 million, up 438%, at a 61% gross margin, all generated by the AME and Quantum segment in its first 86 days after being acquired by
Ness Ziona, Sept. 02, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure
Welcome to the QTEX (QTREX Quantum Ltd.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on QTEX, but look at what you are paying: current EV/EBITDA multiples with 0.7% gross margins. Unless QTREX Quantum Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on QTEX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $1.22 (52-wk range $0.28 - $3.85), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).